NEOPLASMS BY HISTOLOGIC TYPE

This early-stage study tests a new drug called ziftomenib combined with standard treatments for people with a type of acute myeloid leukemia (AML) that has come back or not responded to therapy. The main goal is to check safety and find the best dose. About 171 adults with specif…

This early-stage trial tests a new gene therapy called KLN-1010 for people with multiple myeloma that has come back or not responded to treatment. The therapy works by giving a single injection that instructs the body's own immune cells to become cancer-fighting cells (CAR-T cell…

This study tests a drug called alectinib, already approved for some lung cancers, in people with other rare cancers that have a specific gene change (ALK). About 30 adults, teens, and children will receive the drug to see if it shrinks tumors or stops cancer growth for at least 2…

This early-stage trial tests a specially engineered virus, G207, in children and young adults (ages 3 to 21) whose cerebellar brain tumors have come back or not responded to standard treatments. The virus is injected directly into the tumor, and a single low dose of radiation is …

This study tests atezolizumab, a drug already approved for some cancers, in people with rare cancers that have high tumor mutational burden (TMB), high microsatellite instability (MSI), or a specific DNA repair defect (CMMRD). About 30 adults, teens, and children will receive the…

This study tests a drug called entrectinib, already approved for some lung cancers, in people with rare cancers that have a specific genetic change (ROS1 fusion). About 30 adults and children with these rare tumors will receive the drug. Researchers will measure if tumors shrink …

This study tests capmatinib, a drug already approved for certain lung cancers, in adults with other rare cancers that have specific MET gene changes. About 30 participants will receive the drug to see if their tumors shrink or stop growing for at least 24 weeks. The goal is to fi…